Helsinn's Akynzeo is a combination antiemetic drug used to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. It combines netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-3 (5-HT3) receptor antagonist [2].
What is Akynzeo approved for?
Akynzeo is approved for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy in adults [2]. It is also used for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults [3].
How does Akynzeo work?
Akynzeo targets two key pathways involved in CINV. Netupitant blocks the NK1 receptor, which is responsible for delayed nausea and vomiting. Palonosetron blocks the 5-HT3 receptor, which is involved in acute nausea and vomiting [2]. This dual-action mechanism provides comprehensive protection against both phases of CINV [4].
When does Akynzeo's patent expire?
Patent expiry dates for Akynzeo can vary by region and specific patent. Information on patent status and expiry timelines can be found on DrugPatentWatch.com [5].
What are the common side effects of Akynzeo?
Common side effects reported in clinical trials include fatigue, headache, and constipation [2]. Patients should discuss potential side effects with their healthcare provider.
What are the alternatives to Akynzeo?
Other antiemetic regimens are available for CINV prevention, often involving combinations of different drug classes such as NK1 receptor antagonists, 5-HT3 receptor antagonists, and corticosteroids. The choice of antiemetic therapy depends on the emetogenic potential of the chemotherapy regimen and individual patient factors [4].
Who manufactures Akynzeo?
Akynzeo was developed by Helsinn [1].
What is the clinical data supporting Akynzeo's efficacy?
Clinical trials have demonstrated that Akynzeo is effective in preventing both acute and delayed CINV. Studies have shown high rates of complete response (no vomiting and no rescue medication) in patients receiving Akynzeo compared to other antiemetic combinations [2][4].
Are there any generic versions of Akynzeo available?
The availability of generic versions of Akynzeo depends on patent expiries and regulatory approvals in different countries. Information regarding generic availability can be accessed through resources like DrugPatentWatch.com [5].
What are the risks associated with Akynzeo?
While generally well-tolerated, potential risks and side effects should be discussed with a healthcare professional. Rare but serious side effects can occur [2].
Sources:
[1] https://www.drugpatentwatch.com/drug/akynzeo
[2] https://www.drugpatentwatch.com/drug/netupitant-palonosetron
[3] https://www.drugpatentwatch.com/drug/akynzeo-tablet
[4] https://www.drugpatentwatch.com/drug/akynzeo-capsule
[5] https://www.drugpatentwatch.com/